Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 9 of 5804
-
Double-Barreled CAR t attack shows promise for tough childhood leukemia
Disease control Recruiting nowThis study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).
Phase: PHASE1, PHASE2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New TB vaccine aims to prevent active lung disease in adults
⭐️ VACCINE ⭐️ OngoingThis study is a multicenter, double-blind, randomized, placebo-controlled Phase III trial designed to evaluate the efficacy and safety of the GamTBvac recombinant subunit tuberculosis vaccine for the prevention of active non-HIV-associated pulmonary tuberculosis. The study is di…
Phase: PHASE3 • Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 08, 2026 00:00 UTC
-
Twice-Yearly shot could revolutionize HIV prevention for young women
Prevention OngoingThe goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF) in preventing HIV infection, in adolescent girls and young women (AGYW). The primary objective of this study is to evaluate the efficacy of LE…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated Jun 27, 2026 12:02 UTC
-
Engineered immune cells take on tough lymphomas
Disease control Recruiting nowDALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymp…
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Four-Drug cocktail aims to crush myeloma before transplant
Disease control OngoingThis protocol is a phase III study designed to compare the efficacy and the safety of Isa-KRd induction, transplant, Isa-KRd post ASCT consolidation and Isa-KRd light consolidation vs KRd induction, transplant, KRd post ASCT consolidation and KRd light consolidation After confirm…
Phase: PHASE3 • Sponsor: European Myeloma Network B.V. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New 9-Valent HPV vaccine aims to block more Cancer-Causing viruses
⭐️ VACCINE ⭐️ OngoingThis phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD., in healthy women aged 18-45 years old.
Phase: PHASE3 • Sponsor: Xiamen University • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:58 UTC
-
Ebola vaccine trial aims to shield frontline workers in congo
⭐️ VACCINE ⭐️ CompletedThis Phase 2 study aims to improve preparedness for future Ebola outbreaks by vaccination of a well-known population at risk, ie, a cohort of health care providers (HCP) (such as primary, emergency, and community health care workers) who may be exposed to Ebola in the event of a …
Phase: PHASE2 • Sponsor: Universiteit Antwerpen • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 16, 2026 00:00 UTC
-
New pill takes aim at 'Undruggable' cancer mutation
Disease control CompletedEvaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
One-Time gene therapy could free hemophilia b patients from frequent infusions
Disease control CompletedThis is an open-label, single-dose, multi-center, multinational trial to demonstrate the efficacy of AMT-061 and to further describe its safety profile. The study drug is identified as AAV5-hFIXco-Padua (AMT- 061). AMT-061 is a recombinant adeno-associated viral vector of seroty…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New HIV prevention pill shows promise in large trial
Prevention OngoingThe primary objective of this study is to assess the rates of HIV-1 infection in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) with a mi…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Womb transplants could let infertile women give birth
Disease control OngoingThis study aims to investigate the treatment of absolute uterine infertility (AUI) due to congenital or surgical absence of a uterus or presence of a nonfunctioning uterus. The investigators will follow a model based on a Swedish study to enroll 20 women with functioning ovaries …
Phase: NA • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Massive AML trial aims to find best chemo and transplant protection for younger patients
Disease control Recruiting nowThis open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategie…
Phase: PHASE2, PHASE3 • Sponsor: University Hospital, Angers • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental antibody cocktail offers hope for rabies patients with no other options
Disease control AVAILABLEThis sponsor-initiated Expanded Access Program provides compassionate-use SYN023, a dual monoclonal antibody cocktail (zamerovimab + mazorelvimab) targeting rabies virus glycoprotein, for US patients with confirmed or suspected life-threatening rabies lacking adequate alternative…
Sponsor: Synermore Biologics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug combo aims to boost lymphoma treatment
Disease control Not yet recruitingThis study will treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of birelentinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP.
Phase: PHASE2, PHASE3 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug combo targets tough pancreatic cancer gene
Disease control Not yet recruitingThis study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation.The study consists of two stages I, Stage I :explores the combination dose and the second phase; Stage II :patients were randomized 1:1 to receive either the experimental regime…
Phase: PHASE2, PHASE3 • Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
One shot, two protections? new trial combines dengue and chikungunya vaccines
⭐️ VACCINE ⭐️ Not yet recruitingThis randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the adult population aged 18 to 59 years without prior …
Phase: PHASE3 • Sponsor: Butantan Institute • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 18, 2026 00:00 UTC
-
New trial aims to boost survival in HER2+ breast cancer by adding surgery and radiation to drug therapy
Disease control Not yet recruitingThis phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therap…
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New trial aims to slash deadly complications in Kids' stem cell transplants
Disease control Not yet recruitingBackground: In children with \>120 rare diseases, haematopoietic stem cell transplant (HSCT) provides a medical "reset" for the body, replacing diseased or dysfunctional bone marrow with healthy donor-derived stem cells following high-dose chemotherapy and/or radiotherapy. Howeve…
Phase: NA • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Targeted pill aims to stall a common brain Tumor's growth
Disease control Not yet recruitingThis is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study comparing the efficacy and safety of safusidenib versus placebo in participants with residual or recurrent Grade 2 glioma (oligodendroglioma or astrocytoma) with an IDH1 mutation who have undergone…
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a pill replace chemo for some breast cancers? major trial launches
Disease control Recruiting nowThis phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC